| Date |
Company |
Compound |
Disease |
Type of agreement |
Therapeutic area |
Type of Information |
| 2018-07-24 |
MorphoSys (Germany) |
vie-president |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-07-23 |
Epizyme (USA - MA) |
chief medical officer |
|
nomination |
Cancer - Oncology - Rare diseases |
Nomination |
| 2018-07-23 |
BioInvent (Sweden) ITBMed (Sweden) |
siplizumab |
|
manufacturing - bioproduction |
Transplantation - Technology - Services |
Production agreement |
| 2018-07-23 |
Gamida Cells (Israel) |
chief operating officer - vice president |
|
nomination |
Autoimmune diseases – Immunological diseases - Inflammatory diseases |
Nomination |
| 2018-07-19 |
Novartis (Switzerland) Galapagos (Belgium) Morphosys (Germany) |
MOR106 |
atopic dermatitis |
licensing |
Autoimmune diseases - Dermatological diseases |
Licensing agreement |
| 2018-07-18 |
Tmunity Therapeutics (USA - PA) |
chief medical officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-07-13 |
Sangamo Therapeutics (USA - CA) |
chief technology officer |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-07-10 |
MedImmune (USA - global biologics arm of AstraZeneca (UK) 4D Molecular Therapeutics (USA - CA) |
AAV vectors |
chronic lung disease |
development - commercialisation |
Lung diseases - Respiratory diseases |
Development agreement |
| 2018-07-10 |
BioNTech (Germany) Genevant Sciences (USA - MA) |
five mRNA therapeutic programs for rare diseases with high unmet
medical need |
Rare diseases |
development - commercialisation |
Rare diseases - Genetic diseases |
Development agreement |
| 2018-07-10 |
Allogene Therapeutics (USA - CA) |
scientific advisory board |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-07-09 |
Orchard Therapeutics (UK) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-07-09 |
Benitec Biopharma (Australia) Axovant (UK) |
- BB-301, now named AXO-AAV-OPMD (genetically modified adeno-associated viral vector serotype 9 expressing shRNA as well as a codon-optimised shRNA-insensitive wildtype PABPN1) and five additional gene therapy products in neurological disorders
|
oculopharyngeal muscular dystrophy (OPMD) amyotrophic lateral sclerosis (ALS) frontotemporal dementia (FTD) |
licensing - research - development |
Rare diseases - Genetic diseases - Neurological diseases |
Licensing agreement |
| 2018-07-09 |
Syntimmune (USA - MA) |
chief medical officer |
|
nomination |
Autoimmune diseases |
Nomination |
| 2018-07-03 |
Y-mAbs Therapeutics (USA - NY) MabVax Therapeutics (USA - CA) |
bi-valent ganglioside based vaccine |
neuroblastoma |
licensing |
Cancer - Oncology - Rare diseases |
Licensing agreement |
| 2018-07-02 |
Xyphos Biosciences (USA - CA) |
chief business officer |
|
nomination |
Cancer - Oncology |
Nomination |
| 2018-06-29 |
Orchard Therapeutics (UK) |
chairman of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-06-28 |
Sangamo Therapeutics (USA - CA) |
member of the board of directors |
|
nomination |
Rare diseases - Genetic diseases |
Nomination |
| 2018-06-27 |
Avrobio (USA - MA) |
member of the board of directors |
|
nomination |
Cancer - Oncology - Rare diseases - Genetic diseases - Lysosomal diseases |
Nomination |
| 2018-06-27 |
Adicet bio (USA - CA) |
|
|
nomination |
Cancer - Oncology - Immunological diseases |
Nomination |
| 2018-06-26 |
Gurnet Point Capital (USA - MA) |
senior partner |
|
nomination |
|
Nomination |
